COVID-19 Booster Dose Eligibility in the United States

This site provides historical data related to COVID-19 booster dose eligibility presented on two CDC COVID Data Tracker sites: Vaccinations in the US and Vaccination Equity. Data are updated weekly on Thursdays. Some COVID-19 vaccine recipients are eligible to receive booster doses, and criteria for booster eligibility may change over time. Data and footnotes will be updated to align with the current recommendations. CDC counts people as having “received a booster dose” if they are fully vaccinated and received another dose of any COVID-19 vaccine on or after August 13, 2021. This does not distinguish whether the recipient is immunocompromised and received an additional dose Data Limitations: The booster eligibility metric excludes fully vaccinated recipients who have an “Other” primary series vaccine type. Booster eligibility counts and percentages exclude vaccine administrations reported by Texas as the primary series cannot be linked to booster dose in the aggregate data submitted by Texas. Footnotes: CDC counts people as being “eligible to get a booster dose” if it has been at least 5 months since their completed Pfizer-BioNTech or Moderna primary series or at least 2 months since their completed Janssen (Johnson & Johnson) single-dose vaccine. Beginning December 9, 2021, adolescents ages 16 and 17 years are authorized and recommended to get a Pfizer-BioNTech booster dose at least 6 months after completing the Pfizer-BioNTech primary series. Beginning January 4, 2022, people ages 16 years and older who have completed the Pfizer-BioNTech primary series can get a booster dose at least 5 months after completing the primary series. Beginning January 5, 2022, adolescents ages 12–15 years who have completed the Pfizer-BioNTech primary series can get a Pfizer-BioNTech booster dose at least 5 months after completing the primary series. Beginning January 7, 2022, adults ages 18 years and older who have completed the Moderna primary series can get an mRNA booster dose at least 5 months after completing the primary series. Read less